Limiting the development of secondary damage represents one of the major goals of neuroprotective therapies after spinal cord injury. Here, we demonstrate that specific JNK inhibition via a single intraperitoneal injection of the cell permeable peptide D-JNKI1 6 h after lesion improves locomotor recovery assessed by both the footprint and the BMS tests up to 4 months post-injury in mice. JNK inhibition prevents c-jun phosphorylation and caspase-3 cleavage, has neuroprotective effects and results in an increased sparing of white matter at the lesion site. Lastly, D-JNKI1 treated animals show a lower increase of erythrocyte extravasation and blood brain barrier permeability, thus indicating protection of the vascular system. In total, these r...
Background: Current tools for analgesia are often only partially successful, thus investigations of ...
D-JNKI1, a cell-permeable peptide inhibitor of the c-Jun N-terminal kinase (JNK) pathway, has been s...
Spinal muscular atrophy (SMA) is a severe neurodegenerative disorder that occurs in early childhood....
Limiting the development of secondary damage represents one of the major goals of neuroprotective th...
JNKs (c-Jun N- terminal kinases) are important transducing enzymes involved in many faces of cellula...
The c-Jun N-terminal kinase (JNK) pathway is involved in cell stress and apoptosis. We tested the hy...
BACKGROUND AND PURPOSE: In 2 models of severe ischemic injury, we have evaluated the neuroprotective...
The c-Jun-N-terminal kinase (JNK) pathway has been shown to play an important role in excitotoxic ne...
The c-Jun N-terminal kinases (JNK) belong to the subfamily of mitogen-activated protein kinase (MAPK...
The c-Jun-N-terminal kinase signaling pathway (JNK) is highly activated during ischemia and plays an...
Neuronal death in cerebral ischemia is largely due to excitotoxic mechanisms, which are known to act...
The c-Jun-N-terminal kinase (JNK) plays a key role in ischemia-induced neuronal death. The peptide D...
Neuronal death in cerebral ischemia is largely due to excitotoxic mechanisms, which are known to act...
The c-Jun N-terminal kinases (JNKs) are members of the family of mitogen activated protein kinases (...
Optimal management of neuropathic pain is a major clinical challenge. We investigated the involvemen...
Background: Current tools for analgesia are often only partially successful, thus investigations of ...
D-JNKI1, a cell-permeable peptide inhibitor of the c-Jun N-terminal kinase (JNK) pathway, has been s...
Spinal muscular atrophy (SMA) is a severe neurodegenerative disorder that occurs in early childhood....
Limiting the development of secondary damage represents one of the major goals of neuroprotective th...
JNKs (c-Jun N- terminal kinases) are important transducing enzymes involved in many faces of cellula...
The c-Jun N-terminal kinase (JNK) pathway is involved in cell stress and apoptosis. We tested the hy...
BACKGROUND AND PURPOSE: In 2 models of severe ischemic injury, we have evaluated the neuroprotective...
The c-Jun-N-terminal kinase (JNK) pathway has been shown to play an important role in excitotoxic ne...
The c-Jun N-terminal kinases (JNK) belong to the subfamily of mitogen-activated protein kinase (MAPK...
The c-Jun-N-terminal kinase signaling pathway (JNK) is highly activated during ischemia and plays an...
Neuronal death in cerebral ischemia is largely due to excitotoxic mechanisms, which are known to act...
The c-Jun-N-terminal kinase (JNK) plays a key role in ischemia-induced neuronal death. The peptide D...
Neuronal death in cerebral ischemia is largely due to excitotoxic mechanisms, which are known to act...
The c-Jun N-terminal kinases (JNKs) are members of the family of mitogen activated protein kinases (...
Optimal management of neuropathic pain is a major clinical challenge. We investigated the involvemen...
Background: Current tools for analgesia are often only partially successful, thus investigations of ...
D-JNKI1, a cell-permeable peptide inhibitor of the c-Jun N-terminal kinase (JNK) pathway, has been s...
Spinal muscular atrophy (SMA) is a severe neurodegenerative disorder that occurs in early childhood....